このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study of IPG11406 Tablets in Participants With Lupus Nephritis

2026年11月8日 更新者:Nanjing Immunophage Biotech Co., Ltd

A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety, Efficacy, And Pharmacokinetics Of IPG11406 Tablets In Participants With Lupus Nephritis

Lupus Nephritis (LN) is one of the most serious and common complications of Systemic Lupus Erythematosus (SLE). It is a chronic inflammatory disease triggered by abnormal autoimmunity and the deposition of immune complexes in the kidneys. Approximately 40% to 60% of SLE patients develop lupus nephritis at the onset of the disease, and the cumulative rate of kidney involvement during the course of the disease can even reach 90%.

The goal of this Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety, Efficacy, And Pharmacokinetics Of IPG11406 Tablets In Participants With Lupus Nephritis trial is to evaluate the efficacy ,safety and tolerability of different doses of IPG11406 tablets combined with standard treatment compared to placebo combined with standard treatment in participants with active lupus nephritis.

A total of 4 groups were designed the 10mg IPG11406 tablet group, the 20mg IPG11406 tablet group, the 40mg IPG11406 tablet group,and the placebo group. The ratio among the groups was 1:1:1:1. Participants were randomly assigned to the above 4 dosage groups, with 48 participants planned for each group, totaling approximately 192 participants enrolled.

After randomization, participants will receive a 24-week double-blind treatment, twice daily (BID).They will take the assigned study drug (IPG11406 tablets at 40mg, 20mg, 10mg or placebo) orally.Throughout the 24-week core treatment period, all participants in all groups should continue to receive the standard treatment as prescribed by the protocol.

The primary efficacy endpoint of the renal response will be determined by changes in proteinuria and renal function. For the renal function assessment in the study visits, the glomerular filtration rate will be estimated using the CKD-EPI formula; proteinuria will be evaluated using the urine protein-to-creatinine ratio (based on the 24-hour urine collected).

調査の概要

状態

まだ募集していません

研究の種類

介入

入学 (推定)

192

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • Jiangsu
      • Nanjing、Jiangsu、中国、210008
        • Nanjing DrumTower Hospital
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~70年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Age: 18 - 70 years old (inclusive of 18 and 70), gender not restricted.
  2. Participants must meet the SLICC (Systemic Lupus International Collaborating Clinics, SLICC) criteria and have been diagnosed with systemic lupus erythematosus before screening.
  3. The 24-hour urine total protein of the participants is ≥ 1g or the urine protein-to-creatinine ratio (UPCR) is ≥ 1g/g (based on the collected 24-hour urine sample).
  4. The estimated glomerular filtration rate (eGFR) calculated using the CKD-EPI formula is > 45 ml/min/1.73 m^2.
  5. According to the 2018 International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification criteria, there is active, biopsy-proven type III or IV lupus nephritis (with or without type V); if there is no biopsy result from the 6 months before the screening visit, a biopsy must be conducted during the screening period to determine if the participant meets this inclusion criteria.
  6. According to the researcher's opinion, the participant has active lupus nephritis and requires induction therapy with high-dose glucocorticoids combined with mycophenolate mofetil.
  7. The participant is willing to take oral mycophenolate mofetil (MMF) during the study period. If the participant has previously taken MMF, they can continue with the previous MMF treatment. If the participant has not taken MMF before, it can be initiated based on the baseline.
  8. For participants who are taking drugs that may affect renal function (such as antihypertensive drugs, lipid-lowering drugs), the dose must be stable for at least 4 weeks before randomization and during the study period.
  9. Female participants with reproductive potential (defined as not undergoing surgical sterilization or having been post-menopausal for less than 1 year) must undergo a blood pregnancy test during the screening visit and the result must be negative; female or male participants with reproductive potential must have no pregnancy plans for at least 30 days before the first administration and within 6 months after the study, voluntarily take effective contraceptive measures (see attachment), and have no sperm donation or egg donation plans.
  10. Participants voluntarily participate in the study, understand and sign the informed consent form, and comply with the requirements in the informed consent form.

Exclusion Criteria:

  1. Participants who have previously been treated with the following medications and are expected to still be within the drug washout period when the study drug is administered:

    a. Taltazyme: 2 months; b. Belimumab: 2 months; other biologic B-cell targeted therapies: 2 months; c. Within 2 months before screening or during screening, oral administration of any JAK inhibitor, Bruton's tyrosine kinase (BTK) inhibitor, or tyrosine kinase 2 (TYK2) inhibitor, including baricitinib, tofacitinib, upadacitinib, fingolimod, ibrutinib, or fenbetidine; d. Participants who have received CAR-T therapy cannot be enrolled. e. Within less than 9 months before screening or during screening, any anti-CD20 therapy (such as rituximab, ofatumumab, or oriximab), CD19 targeted therapy, if received between 9 and 12 months before screening, peripheral blood CD19⁺ B cell count must be ≥ 25 cells/μL.

  2. Participants who received cyclophosphamide (CYC) induction therapy within 1 month before screening.

  3. Participants who used any immunomodulatory drugs or herbal preparations with potential impact on liver and kidney function within 4 weeks before screening, including but not limited to Tripterygium glycosides tablets, drugs containing aristolochic acid (such as Dragon's Liver-Clearing Pills, Coronary Heart-Soothing Pills, etc.), and known hepatotoxicity-laden ingredients such as Notoginseng and Tongshiguaiwu.

  4. Participants with interstitial fibrosis/tubular atrophy (IF/TA) or glomerular sclerosis exceeding 50% in renal tissue biopsy.

  5. Participants with rapidly progressive glomerulonephritis, as defined by any of the following:

    • Renal biopsy assessment shows that ≥ 50% of glomeruli have crescent formation
    • Serum creatinine has continuously doubled within 2 months before screening
    • The investigator believes that the participant has rapidly progressive glomerulonephritis
  6. Primary glomerular diseases or secondary nephropathy caused by systemic lupus erythematosus, including diabetic nephropathy, hypertensive renal damage, anti-glomerular basement membrane disease, viral hepatitis-related nephropathy, HIV-related nephropathy, purpura nephritis, paraproteinemia-related nephropathy, drug or toxin-related nephropathy, etc., which the investigator believes may interfere with LN assessment and will interfere with the assessment results of disease activity.

  7. Participants at the time of screening visit still have ≥ 2 grade adverse events related to previous drug treatment (see the main text of the protocol - adverse event grading), or adverse events that affect the participant's inclusion/exclusion criteria judgment and/or participant's efficacy/safety assessment.

  8. Participants who previously had or currently have severe neuropsychiatric SLE, including but not limited to the following: seizure, new or worsening impairment of consciousness, psychosis, delirium or confusion state, sterile meningitis, ascending or transverse myelitis, chorea, cerebellar ataxia, multiple mononeuritis, demyelinating syndrome or situations that prevent the participant from fully understanding ICF.

  9. Any overlapping autoimmune diseases whose condition or treatment may affect the assessment or outcome of this study (such as scleroderma with significant pulmonary hypertension; any disease that requires additional immunosuppressive treatment), must be excluded. If the condition or treatment of overlapping diseases is expected not to affect the assessment or outcome of the study (such as Sjogren's syndrome), it is not excluded. Participants.

  10. Participants who have had malignant tumors within the past 5 years.

  11. Participants with active antiphospholipid antibody syndrome (APS) or requiring therapeutic anticoagulation.

  12. Participants currently requiring renal dialysis (hemodialysis or peritoneal dialysis), or expected to require renal dialysis during the study.

  13. Participants with a history of major organ transplantation (such as heart, lung, kidney, liver) or hematopoietic stem cell/marrow transplantation.

  14. Participants who have undergone major surgical procedures (craniotomy, thoracotomy or laparotomy) within the previous 4 weeks or have unhealed wounds, ulcers or fractures.

  15. Participants who have received live/dead attenuated vaccinations or plan to receive live/dead attenuated vaccinations during the trial.

  16. Participants with any of the following cardiac impairments: a. New York Heart Association functional classification grade III to IV; b. Uncontrolled angina pectoris, congestive heart failure or myocardial infarction within 6 months before the first dose administration; c. QTcF interval prolonged by Fridericia formula (male > 450 milliseconds; female > 470 milliseconds); d. Second-degree type II atrioventricular (AV) block, third-degree AV block or PR interval > 250 milliseconds, etc.; e. Various factors that may increase the risk of QTcF prolongation or arrhythmia events, such as heart failure, hypokalemia, congenital long QT syndrome, and first-degree relatives in the family history had sudden death before the age of 40; f. Left ventricular ejection fraction (LVEF) < 50%.

  17. Participants who are receiving treatment for chronic or recurrent infections, such as tuberculosis, pneumocystis pneumonia, herpes simplex virus and varicella-zoster virus.

  18. Participants with positive HBsAg in the five-antibody test for hepatitis B (those with negative HBsAg but positive HBcAb need to do HBV-DNA quantitative test; those with HBV-DNA test result ≥ upper limit of reference value of each center or those requiring antiviral treatment do not meet the conditions for participating in the study); positive hepatitis C antibody (add HCV-RNA test if negative; those who are negative can be enrolled); positive Treponema pallidum antibody (if Treponema pallidum antibody is positive, further Treponema pallidum serological test is conducted; participants judged by the investigator as having had a past infection with syphilis but having been cured meet the inclusion criteria); positive HIV antibody test.

  19. Participants with significantly abnormal liver, kidney function and blood routine test results, including: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) exceeding 2 times the upper limit of normal value, serum total bilirubin exceeding 1.5 times the upper limit of normal value; hemoglobin < 90 g/L; white blood cell count < 3.0×10^9/L, platelet count (PLT) < 75×10^9/L; neutrophil count < 1.0×10^9/L; and other abnormal laboratory test results, as determined by the investigator, may affect the participant's ability to complete the entire clinical research process or interfere with the safety/efficacy results of the study.

  20. Participants have any condition that may prevent them from safely completing all clinical research procedures, such as being allergic to the test drug (including excipients), having a severe allergic disease or being of an allergic constitution, having a known difficulty in swallowing, experiencing anemias or needle phobia, being intolerant to oral or intravenous glucocorticoids or having contraindications, or being intolerant to mycophenolate mofetil.

  21. Participants have any of the following major infection events:

    • Hospitalized within the previous 8 weeks or during the screening period
    • Received intravenous antibiotics or anti-infective drugs during the screening period
    • Received oral antibiotics or anti-infective drugs within the previous 2 weeks or during the screening period
  22. Note: If only using antibiotics or anti-infective drugs without major infection events does not constitute an exclusion criterion.

  23. Participants have a history of drug abuse or drug misuse.

  24. Pregnant or lactating female participants.

  25. Participants who have participated in other clinical studies within 180 days before the screening, or who plan to participate in other clinical studies before the completion of all planned visits of this clinical study;

  26. Other situations judged by the investigator as not suitable for inclusion.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
プラセボコンパレーター:プラセボグループ

Twice daily, oral administration for 24 weeks.

実験的:10mg IPG11406 tablet group

Twice daily, oral administration for 24 weeks.

Twice daily, oral administration for 24 weeks.

実験的:20mg IPG11406 tablet group

Twice daily, oral administration for 24 weeks.

Twice daily, oral administration for 24 weeks.

実験的:40mg IPG11406 tablet group

Twice daily, oral administration for 24 weeks.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
The proportion of participants who achieved complete renal remission (Completerenalresponse, CRR) at the 24th week.
時間枠:From enrollment to the end of treatment at 24 weeks

The definition of CRR is as follows:

  1. The urine protein/urine creatinine ratio (UPCR, based on the 24-hour urine sample collected) is less than 0.5g/g;
  2. The reduction in glomerular filtration rate (eGFR) is ≤ 15% of the baseline value or eGFR is ≥ 90 mL/min/1.73m^2;
  3. There are no concurrent conditions such as rescue treatment, treatment failure, death, or withdrawal from the study.
From enrollment to the end of treatment at 24 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年11月20日

一次修了 (推定)

2028年11月20日

研究の完了 (推定)

2029年11月20日

試験登録日

最初に提出

2026年11月8日

QC基準を満たした最初の提出物

2026年11月8日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月8日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

未定

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する